Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer
- Author(s)
- Yazaki, S; Salgado, R; Shimoi, T; Yoshida, M; Shiino, S; Kaneda, T; Kojima, Y; Sumiyoshi-Okuma, H; Nishikawa, T; Sudo, K; Noguchi, E; Murata, T; Takayama, S; Suto, A; Ohe, Y; Yonemori, K;
- Journal Title
- British Journal of Cancer
- Publication Type
- Research article
- Abstract
- BACKGROUND: Chemotherapy and radiotherapy were postulated to induce an inflamed tumour microenvironment. We aimed to evaluate the effects of adjuvant chemotherapy/radiotherapy on tumour-infiltrating lymphocytes (TILs) and programmed death-ligand 1 (PD-L1) expression in metastatic breast cancer. METHODS: We identified paired primary and metastatic tumours in 85 patients with breast cancer. Stromal TILs were assessed according to international guidelines. PD-L1 expression was evaluated using the VENTANA SP142 assay. RESULTS: TILs were significantly lower in metastatic tumours than in primary tumours (12.2 vs. 8.3%, p = 0.049). PD-L1 positivity was similar between primary and metastatic tumours (21.2 vs. 14.1%, p = 0.23). TILs were significantly lower in patients who received adjuvant chemotherapy than in those who did not (-9.07 vs. 1.19%, p = 0.01). However, radiotherapy had no significant effect on TILs (p = 0.44). Decreased TILs predicted worse post-recurrence survival (hazard ratio, 2.94; 95% confidence interval [CI]: 1.41-6.13, p = 0.003), while increased TILs was associated with a better prognosis (HR, 0.12; 95% CI: 0.02-0.08, p = 0.04). CONCLUSIONS: TILs decreased in metastatic tumours, particularly in patients who relapsed after adjuvant chemotherapy. Changes in TILs from primary to metastatic sites could be a prognostic factor after recurrence.
- Publisher
- Springer Nature
- Keywords
- Humans; Female; *Breast Neoplasms/pathology; B7-H1 Antigen/metabolism; Lymphocytes, Tumor-Infiltrating/pathology; Prognosis; Chemotherapy, Adjuvant; Tumor Microenvironment
- Department(s)
- Medical Oncology
- PubMed ID
- 36522476
- Publisher's Version
- https://doi.org/10.1038/s41416-022-02072-2
- Open Access at Publisher's Site
http://doi.org/10.1038/s41416-022-02072-2- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-01-23 05:07:06
Last Modified: 2024-07-30 02:16:28